Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 174

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 1A
Chunk 174
---
 company “butterfly reorganization” rules in Section 55 of the Income Tax Act (Canada) (the “Tax Act”), certain requirements of those rules depend on events that may not be within our control;•We potentially could have received better terms from unaffiliated third parties than the terms we received in our agreements with BHC; •The potential indemnification obligations to BHC and the ability of BHC to satisfy its corresponding indemnification obligations to us;•As long as BHC owns a majority of our common shares, we may rely on certain exemptions from the corporate governance requirements of the NYSE available to “controlled companies” and of the TSX available to “majority controlled” companies;•The impact of the actual or perceived future sales of our common shares on our common share price; •Our ability to successfully develop our pipeline of products, which is highly uncertain and requires significant expenditures and time, including risks relating to obtaining necessary government approvals;•Failure to comply with post-approval legal and regulatory requirements for our marketed products;

16

•Interruptions to our manufacturing operations and those of our third-party manufacturers, including as a result of failure to comply with applicable regulations;•Certain of our products or components thereof are available from a single source or a limited number of sources;•Issues relating to inventory levels or fluctuations in buying patterns by our large distributors and retail customers and supply chain disruptions;•Failure to yield new products that achieve commercial success;•Changes in market acceptance of our products due to inadequate reimbursement for such products or otherwise.•The impact of competition and new medical and technological developments in our markets;•The loss of the services of, or our inability to recruit, retain, motivate, our executives and other key employees;•Pricing decisions, including as a result of price changes and/or new programs to enhance patient access to our products;•Failure to maintain our relationships with health care providers who recommend our products to their patients;•Our inability to control certain aspects of our third party distribution arrangements:•The impact on our revenues of our policies and programs relating to returns, allowances, chargebacks and marketing;•Risks associated with wholesaler concentration;•Acquisition and integration risks; •Potential obligations under our indemnity agreements and arrangements;•Environmental, social and governance (ESG) matters and our ability to monitor and respond appropriately;•Our indebtedness could adversely affect our business and our ability to meet our obligations;•International operations risks associated with conducting a significant portion of our business outside the United